Recent Quotes (30 days)

You have no recent quotes
chg | %

Benitec Biopharma Ltd  

(Public, ASX:BLT)   Watch this stock  
Find more results for ASX: BLT
+0.030 (20.00%)
Oct 18 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.17 - 0.19
52 week 0.09 - 0.28
Open 0.18
Vol / Avg. 1.63M/126,100.00
Mkt cap 36.93M
P/E     -
Div/yield     -
EPS -0.03
Shares 205.14M
Beta     -
Inst. own     -
Sep 12, 2017
Benitec Biopharma Ltd at Rodman & Renshaw Global Investment Conference
Aug 30, 2017
Preliminary 2017 Benitec Biopharma Ltd Earnings Call
Aug 29, 2017
Preliminary 2017 Benitec Biopharma Ltd Earnings Release
Jul 27, 2017
Banat Fabrika Ulja ad Nova Crnja Annual Shareholders Meeting (Estimated)

Key stats and ratios

Q2 (Jun '17) 2017
Net profit margin -191.16% -51.29%
Operating margin -182.84% -48.83%
EBITD margin - -46.88%
Return on average assets -42.70% -26.74%
Return on average equity -44.89% -28.21%
Employees 13 -
CDP Score - -


SE 1201 99 Mount St
+61-2-95556986 (Phone)
+61-2-98182238 (Fax)

Website links


Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.

Officers and directors

Gregory West Chief Executive Officer, Company Secretary
Bryan Dulhunty Chief Financial Officer
Clifford Michael Holloway Chief Business and Operating Officer
Age: 57
Michael Graham Chief Scientific Officer
Jerel A. Banks M.D., Ph.D. Non-Executive Chairman of the Board
Kevin Buchi CPA Director
Megan Joan Boston Non-Executive Director
Peter Damian Francis Non-Executive Director
John C. Chiplin Ph.D. Non-Executive Independent Director
Age: 57